Predicting Success in the Biotech and Pharma Sectors Mark Schoenebaum of ISI Group earned two top spots on this year's All-America Research Team. Here he explains how he differentiates the good stocks from the bad. Related Articles Edgar Allen’s High Ground Beats the Market Despite Shunning AI Stocks Stephen Taub For Members Only Biopharma’s Sickly September Stephen Taub A Different Ask of Global Equities as Investors Seek Downside Protection Sponsored by Schroders